Welcome to our dedicated page for Intelgenx Technologies news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on Intelgenx Technologies stock.
Intelgenx Technologies Corp (IGXT) specializes in advanced drug delivery solutions for pharmaceutical partners worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's proprietary technologies, strategic collaborations, and regulatory progress.
Track critical developments including formulation advancements, clinical trial milestones, manufacturing expansions, and partnership announcements. Our curated collection ensures timely access to verified press releases and objective reporting on IGXT's role in enhancing therapeutic outcomes through innovative delivery systems.
Discover updates spanning key operational areas: regulatory submissions for improved drug formulations, strategic licensing agreements with global partners, and manufacturing scale-up initiatives for optimized production. Bookmark this page for direct access to Intelgenx's official communications and third-party analyses of their pharmaceutical development progress.
IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) announced major changes to its management team following the retirement of founder and CEO Horst G. Zerbe. Dwight Gorham has been appointed as the new CEO, with previous roles at Pillar 5 Pharma and Pharmascience. The FDA has set a PDUFA goal date of April 17, 2023, for the review of IntelGenx's RIZAFILM® NDA, and an ANDA for the Buprenorphine Buccal Film due April 28, 2023. Other key appointments include Dr. David Kideckel as Head of Corporate Development and Tommy Kenny as Senior Vice President, General Counsel. These leadership changes are aimed at enhancing the company's growth and preparing for the potential commercialization of its proprietary oral film products.
IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) reported its financial results for Q4 and the full year 2022. For the fourth quarter, revenue declined to $173,000, down 65% from $494,000 in Q4 2021. Net comprehensive loss improved to $2.3 million from $2.9 million in the same quarter last year. For the full year, revenue decreased 38% to $1.0 million, with a net comprehensive loss of $11.6 million compared to $9.8 million in 2021. Key developments include a $3.0 million term loan received and an upcoming FDA decision on RIZAFILM®. The Company's cash position was $2.5 million as of December 31, 2022.
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) has announced the release date for its fourth quarter and full year 2022 financial results, set for March 29, 2023, after market close.
The announcement follows a prior press release and will include a conference call at 4:30 p.m. ET, featuring CEO Dr. Horst G. Zerbe and CFO Andre Godin. Investors can join via a dedicated phone line or view the webcast on IntelGenx's website. As a leader in pharmaceutical films, IntelGenx focuses on innovative solutions for unmet medical needs, leveraging advanced technologies like VersaFilm and DisinteQ.
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) will announce its fourth quarter and full year 2022 financial results after the market closes on March 30, 2023. The announcement will be followed by a conference call featuring CEO Dr. Horst G. Zerbe and CFO Andre Godin, discussing the results and providing a business update. The call is set for 4:30 p.m. ET, accessible via a toll-free number for Canada and the U.S. as well as an international line. IntelGenx specializes in pharmaceutical films and aims to tackle unmet medical needs through its innovative drug delivery technologies.
IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) has completed a private placement offering, raising approximately US$760,000 (C$1,000,000) through convertible notes due March 1, 2027. The notes carry an interest rate of 10% per annum, payable quarterly, and can convert into common stock at US$0.20 per share after six months. Proceeds will finance IntelGenx's Rizaport and Buprenorphine programs and support working capital. The TSX has conditionally approved the listing of shares related to the offering, pending fulfillment of listing requirements.
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) will participate in the 35th Annual ROTH Conference from March 12–14, 2023, at the Ritz-Carlton Hotel in Dana Point, California. The company's President and CFO, Andre Godin, will engage in a fireside chat on March 14 at 11:30 PM Pacific Time, hosted by Jonathan Aschoff, Ph.D. Additionally, one-on-one meetings with investors will be held during the event. IntelGenx specializes in innovative drug delivery systems, providing advanced pharmaceutical films aimed at addressing unmet medical needs. For more information, visit www.intelgenx.com.
IntelGenx Corp. (IGXT) announced the granting of a Notice of Allowance for a U.S. patent covering its Loxapine oral film formulations, designed for patients with anxiety and agitation associated with schizophrenia and bipolar 1 disorder. This formulation aims to facilitate quicker administration compared to traditional inhalers, which require physician supervision. CEO Horst G. Zerbe emphasized that this patent solidifies long-term market exclusivity for the Loxapine VersaFilm®, enhancing the company's intellectual property portfolio and addressing unmet medical needs in mental health treatments.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has announced a research collaboration with Dr. Per Svenningsson from the Karolinska Institute to conduct a multicentre, randomized, double-blind, placebo-controlled clinical study. This study will investigate the efficacy of IntelGenx’s Montelukast VersaFilm® for treating Parkinson’s Disease (PD). Funded by a 20 million Swedish Crowns grant (approximately $2 million USD), the study aims to commence in Q3 2023. Upon completion, IntelGenx will retain intellectual property rights related to the findings, which could enhance the development of Montelukast for neurodegenerative diseases.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has signed an exclusive supply agreement with ARWAN Pharmaceuticals to distribute RIZAPORT® in the MENA region, including countries like Lebanon, Saudi Arabia, and Egypt. RIZAPORT®, an oral thin film formulation of rizatriptan benzoate, offers an alternative treatment for migraines, especially beneficial for patients with nausea or swallowing difficulties. This partnership leverages ARWAN's local market expertise to maximize the product's reach. IntelGenx aims to enhance its market presence while addressing an urgent healthcare need in the region.
